23.03.2013 Views

White Guide and Orange Guide Formatting Project - Pfizer

White Guide and Orange Guide Formatting Project - Pfizer

White Guide and Orange Guide Formatting Project - Pfizer

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Orange</strong> <strong>Guide</strong> – Chapter 14: CGC Tools <strong>and</strong> Resources<br />

legitimate reasons as determined by CGC Legal <strong>and</strong> the Channel Strategy & Solutions Group), the<br />

proposed modifications must be approved by a <strong>Pfizer</strong> Review Committee before being provided to a<br />

customer. Keep in mind that Quality Programs that underwrite operational services or provide services<br />

that the customer would be obligated to obtain on its own will not receive approval by the <strong>Pfizer</strong><br />

Review Committee.<br />

The Value of Quality Programs in Meeting Objectives<br />

Quality Program Recipients<br />

Q. I know I cannot conduct a financial return on investment (ROI) analysis on<br />

Quality Programs since they are not to be tied to prescribing. Can I conduct any<br />

analysis to determine whether the Quality Program was valuable to the<br />

customer?<br />

A. Non-financial ROI analyses, like measuring whether a program has improved<br />

patient or physician underst<strong>and</strong>ing of a disease or enhanced the ability of<br />

physicians to effectively discuss sensitive issues with patients, are appropriate<br />

to conduct in order to determine whether the Quality Program met its objective<br />

of improving patient outcomes or increasing physician underst<strong>and</strong>ing.<br />

Quality Programs must be made widely available to our customers who meet certain capability criteria<br />

as part of <strong>Pfizer</strong>’s overall mission to enhance the quality of healthcare. Offering the programs to only<br />

select customers could be perceived as providing items of value in order to increase prescribing or<br />

improve formulary status in violation of the anti-kickback laws or other healthcare laws.<br />

To ensure that the offering of these programs does not violate applicable law, you must never provide a<br />

Quality Program to a customer in exchange for increased prescribing or improved formulary status.<br />

Even though a customer may decide to change prescribing habits or formulary status based on the<br />

information it receives from a Quality Program, you should never make these changes a condition of<br />

receiving the program.<br />

224<br />

Rev. 09/12<br />

Page 5 of 7

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!